Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 25.65 USD 2.07% Market Closed
Market Cap: 145.4B USD
Have any thoughts about
Pfizer Inc?
Write Note

Pfizer Inc
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pfizer Inc
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Pfizer Inc
NYSE:PFE
Other Receivables
$3.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Other Receivables
$5.2B
CAGR 3-Years
10%
CAGR 5-Years
37%
CAGR 10-Years
14%
Merck & Co Inc
NYSE:MRK
Other Receivables
$793m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zoetis Inc
NYSE:ZTS
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Other Receivables
$1.8B
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pfizer Inc
Glance View

Market Cap
145.4B USD
Industry
Pharmaceuticals

Pfizer Inc. is a global leader in the pharmaceutical industry, renowned for its commitment to innovative research and development that drives breakthroughs in healthcare. Founded in 1849, Pfizer has evolved into a powerhouse, particularly highlighted by its pivotal role in developing one of the first COVID-19 vaccines in collaboration with BioNTech. This achievement not only underscored the company's rapid response capabilities but also significantly boosted its revenue, showcasing its ability to pivot in times of global health crises. Investors are drawn to Pfizer not just for its historical legacy, but also for its diverse portfolio that includes treatments across various therapeutic areas such as oncology, immunology, and neurology, reflecting a balanced strategy poised for future growth. As Pfizer continues to navigate a post-pandemic world, its focus on innovation remains a cornerstone of its business strategy. With a robust pipeline of drugs in late-stage development and a strong commitment to mergers and acquisitions, Pfizer is determined to maintain market leadership while expanding its therapeutic offerings. Importantly, the company is also committed to shareholder value, consistently returning profits through dividends and share buybacks. For investors, Pfizer represents a compelling opportunity, merging stability with the potential for growth in an ever-evolving healthcare landscape, driven by advancements in science and technology.

PFE Intrinsic Value
24.05 USD
Overvaluation 6%
Intrinsic Value
Price

See Also

What is Pfizer Inc's Other Receivables?
Other Receivables
3.7B USD

Based on the financial report for Sep 29, 2024, Pfizer Inc's Other Receivables amounts to 3.7B USD.

What is Pfizer Inc's Other Receivables growth rate?
Other Receivables CAGR 1Y
-6%

Over the last year, the Other Receivables growth was -6%.

Back to Top